Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. The divestment of this position is in line with Malin's stated strategy of realising capital from the Growth Potential Asset group as assets mature to optimal value inflection points.' 'The net proceeds that we will receive from this transaction will strengthen our capital position, reducing our outstanding EIB debt, as we look forward to several clinical milestones in our Priority Asset group in 2020. The excellence of the technology is testament to the innovation and dedication of 3D4Medical founder and CEO John Moore along with his exceptional team. The sale of 3D4Medical, one of Malin's Growth Potential Assets, will generate net cash proceeds of over €17 million for Malin, representing a 10% premium to the estimated fair value of Malin's stake in 3D4Medical at 30 June 2019.ĭarragh Lyons, Chief Executive of Malin and 3D4Medical Board Director, said : '3D4Medical has established itself as a global leader in 3D anatomy technology, disrupting traditional methods of education with its innovative technology platform. Elsevier is a global leader in anatomy education and content, with world leading brands including Netter, Gray's Anatomy, Sobotta and McMinn & Abrahams'. (Euronext Growth Dublin:MLC) ('Malin'), a company investing in highly innovative life sciences companies, today announces that 3D4Medical Limited ('3D4Medical'), an award-winning 3D medical technology company, has been sold to Elsevier, part of RELX plc.

Divestment consistent with strategy for Growth Potential Asset Groupĭublin-Ireland, 27 November 2019 : Malin Corporation plc.

3d4medical limited